You are here: Industry Insights > NICE

News List

NICE to simplify how medicines are selected for evaluation europeanpharmaceuticalreview
October 14, 2020
NICE has launched a public consultation for suggestions on updating how it selects the topics to develop guidance on, to improve medicine evaluations.
NICE turns down Celgene's Revlimid as multiple myeloma maintenance treatment pharmatimes
September 23, 2020
The National Institute for Heath and Care Excellence (NICE) has turned down NHS funding of Celgene's Revlimid (lenalidomide) as maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma in adults.
NICE u-turn sees Akcea's Waylivra win NHS funding pharmatimes
September 21, 2020
Akcea Therapeutics UK's Waylivra (volanesorsen), the first and only therapy for Familial Chylomicronaemia Syndrome (FCS), will be funded on the NHS after all, following a u-turn by the National Institute for Health and Care Excellence (NICE).
BMS' Opdivo wins new NICE lung cancer backing pharmatimes
September 21, 2020
NICE has published draft guidance recommending Bristol-Myers Squibb's Opdivo (nivolumab) as a second-line treatment option for patients with squamous or non-squamous non-small-cell lung cancer (NSCLC).
NICE unites with global health leaders to highlight evidence-based healthcare pharmatimes
September 17, 2020
The UK’s National Institute for Health and Care Excellence (NICE) has joined a global initiative focused on bringing evidence-based healthcare to the fore worldwide.
NICE no for Pierre Fabre's Braftovi pharmatimes
September 17, 2020
The National Institute for Health and Care Excellence has published the outcome of an appraisal of Pierre Fabre's Braftovi (encorafinib), turning down NHS funding for the drug as a treatment for some patients with advanced colorectal cancer.
NICE backing for AZ' Tagrisso pharmatimes
September 15, 2020
AstraZeneca's Tagrisso (osimertinib) has been recommended for use within NHS England, in line with its licensed indication, for adults with untreated locally-advanced or metastatic epidermal growth factor receptor (EGFR) ...
NICE backs Portola's Ondexxya pharmatimes
September 14, 2020
The National Institute for Health and Care Excellence (NICE) has published the outcome of an appraisal consultation document backing NHS funds for restricted use of Portola's Ondexxya (andexanet alfa) as an option for reversing anticoagulation ...
Janssen disappointed with second NICE no for Spravato pharmatimes
September 04, 2020
Janssen says it is disappointed with second draft guidance from the National Institute for Health and Care Excellence (NICE) rejecting NHS funds for its nasal depression spray Spravato (esketamine).
NICE green light for immunotherapy Bavencio pharmatimes
September 03, 2020
The National Institute for Health and Care Excellence (NICE) has now published final guidelines endorsing NHS use of Merck and Pfizer's immunotherapy Bavencio (avelumab) in combination with axitinib as a first-line treatment for kidney cancer.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 41 42 Next page